SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2

37Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Tumor angiogenesis is a key feature of cancer progression, because a tumor requires abundant oxygen and nutrition to grow. Here, we demonstrate that SH003, a mixed herbal extract containing Astragalus membranaceus (Am), Angelica gigas (Ag) and Trichosanthes Kirilowii Maximowicz (Tk), represses VEGF-induced tumor angiogenesis both in vitro and in vivo. SH003 inhibited VEGF-induced migration, invasion and tube formation in human umbilical vein endothelial cells (HUVEC) with no effect on the proliferation. SH003 reduced CD31-positive vessel numbers in tumor tissues and retarded tumor growth in our xenograft mouse tumor model, while SH003 did not affect pancreatic tumor cell viability. Consistently, SH003 inhibited VEGFstimulated vascular permeability in ears and back skins. Moreover, SH003 inhibited VEGF-induced VEGFR2-dependent signaling by blocking VEGF binding to VEGFR2. Therefore, our data conclude that SH003 represses tumor angiogenesis by inhibiting VEGF-induced VEGFR2 activation, and suggest that SH003 may be useful for treating cancer.

Author supplied keywords

Cite

CITATION STYLE

APA

Choi, H. S., Kim, M. K., Lee, K., Lee, K. M., Choi, Y. K., Shin, Y. C., … Ko, S. G. (2016). SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2. Oncotarget, 7(22), 32969–32979. https://doi.org/10.18632/oncotarget.8808

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free